Journals / Turkish Journal of Endocrinology and Metabolism / 2021 / Cilt: 25 - Sayı: 2

Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients

Akromegali Hastalarında Solunum Fonksiyonu ve Serum Karboksimetil-Lizin Seviyesinin Değerlendirilmesi

Pages
151–157
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies need to evaluate the association between the advanced glycation end-products and complications of acromega

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate the pulmonary function tests(PFTs) and serum carboxymethyl-lysine (CML) level and their asso-ciation with the disease activity in patients with acromegaly.
📊
Key Findings & Data:Mate- rial and Methods: This cross-sectional study included 65acromegalic patients (F/M:28/37) and 52 controls ( F/M:23/29).
💡
Conclusion & Impact:Future studies need to evaluate the association between the advanced glycation end-products and complications of acromega
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to evaluate the pulmonary function tests(PFTs) and serum carboxymethyl-lysine (CML) level and their asso-ciation with the disease activity in patients with acromegaly. Mate- rial and Methods: This cross-sectional study included 65acromegalic patients (F/M:28/37) and 52 controls ( F/M:23/29). PFTs such as spirometry and diffusing capacity of the lungs for carbon mo-noxide (DLCO) were performed to determine the lungs’ ability to exc-hange gases. Serum CML levels were measured with the enzyme-linked immunosorbent assay. Basal and nadir growth hor-mone (GH), hemoglobin A1c (HbA1c), and insulin-like growth factor-1 (IGF-1) were also assessed. Results: Serum CML levels weresignificantly higher in acromegalic patients (208.1±80 ng/mL) than in controls (174.2±11 ng/mL), (p=0.02). The evaluated PFTs were expressed as predicted values [forced expiratory volume in the 1st second % (p=0.01), forced vital capacity % (p=0.007), functional residual capacity % (p=0.03), residual volume % (p=0.03), vital ca-pacity % (p=0.007), total lung capacity % (p=0.01), and DLCO% (p=0.02)] that were found to be elevated in acromegalic patients than in controls. CML levels positively correlated with HbA1c (r=0.53, p=0.02) but did not correlate with basal GH levels (r=0.35, p=0.06). GH and IGF-1 levels positively correlated with lung volume in acro-megalic patients. Conclusion: Serum CML levels increased in acro- megaly patients but had no association with the PFTs results. Increased lung volume was the most prominent lung function altera-tion in acromegalic patients; relevantly, we found elevated GH and IGF-1 levels to be associated with the increased lung volumes. Future studies need to evaluate the association between the advanced glycation end-products and complications of acromega

Özet

Amaç: Bu çalışmada akromegali hastalarında solunum fonksiyonları,serum karboksimetil-lizin [carboxymethyl-lysine (CML)] seviyeleri ve hastalık aktiviyeleriyle ilişkilerini değerlendirmeyi amaçladık. Gereç veYöntemler: Bu kesitsel çalışmaya 65 akromegali hastası (K/E: 28/37)ve 52 kontrol (K/E: 23/29) olgusu dâhil edilmistir. Solunum fonksiyon testleri (SFT) spirometri ile gaz değişimi ise karbon monoksit difüzyonkapasitesi [diffusing capacity of the lungs for carbon monoxide (DLCO)] ile değerlendirilmiştir. Serum CML düzeyi enzim bağımlı immünosor- bent ölçüm metoduyla ölçülmüştür. Hemoglobin A1c (HbA1c), insülinbenzeri büyüme faktörü-1 [insulin-like growth factor-1 (IGF-1)], bazal ve nadir büyüme hormonu (BH) düzeyleri ölçülmüştür. Bulgular:Serum CML seviyeleri akromegali hastalarında (208,1±80 ng/mL),kontrol hastalarına göre (174,2±11 ng/mL) belirgin olarak daha yük- sekti (p=0,02). SFT ve DLCO; akromegali hastalarında kontrol grubunagöre anlamlı olarak daha yüksek saptandı [% birinci saniyedeki zorluekspiratuar volüm (p=0,01), % zorlu vital kapasite (p=0,007), % fonk-siyonel rezidüel kapasite (p=0,03), % kalıntı hacim (p=0,03), % vitalkapasite (p=0,007), % total akciğer kapasitesi (p=0,01) ve %DLCO(p=0,02)]. CML düzeyi; HbA1c ile pozitif korelasyon gösterirken, (r=0.53, p=0.02), bazal BH ile korelasyon mevcut değildi (r=0.35,p=0.06). Akromegali hastalarında BH ve IGF-1 düzeyleriyle akciğerkapasitesi arasında pozitif korelasyon mevcuttu. Sonuç: Serum CMLdüzeyleri akromegali hastalarında yükselmiştir, ancak SFT ile arasındabir ilişki gösterilememiştir. Artmış akciğer kapasitesi akromegali hasta- larında en sık görülen solunum fonksiyon değişikliğidir ve artmış BH veIGF-1 düzeyleriyle arasında bir ilişki mevcuttu. İleri glikasyon son ürün- leri ve akromegali komplikasyonları arasındaki ilişkinin gösterilebilmesiiçin daha fazla çalışmaya ihtiyaç vardır.

🔖

Cite This Article

YAŞAR, M., KARAKURT, S., UYGUR, M. M., YAVUZ, D. G., YALI, A. S. (2022). Pulmonary Function and Serum Carboxymethyl- Lysine Level Evaluation in Acromegaly Patients. Turkish Journal of Endocrinology and Metabolism, Cilt: 25 - Sayı: 2, 151–157. https://ajindex.com/articles/143965

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a ret- rospective cohort study. United Kingdom Acrome- galy Study Group. J Clin Endocrinol Metab. 1998; 83:2730-2734. [Pubmed] 2. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86:293-299. [Pubmed] 3. Colao A, Ferone D, Marzullo P, Lombardi G. Syste- mic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25:102-52. [Crossref] [Pubmed] 4. Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN. Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res. 2013;45:314-318. [Crossref] [Pubmed] 5. Yang P, Feng J, Peng Q, Liu X, Fan Z. Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes. Oxid Med Cell Lon- gev. 2019;6; 2019:9570616. [Crossref] [Pubmed] [PMC] 6. Kruse CPS, Cottrill DA, Kopchick JJ. Could calgranu- lins and advanced glycated end products potentiate acromegaly pathophysiology? Growth Horm IGF Res. 2019;46-47:1-4. [Crossref] [Pubmed] 7. Davidson MB. Effect of growth hormone on car- bohydrate and lipid metabolism. Endocr Rev. 1987; 8:115-131. [Crossref] [Pubmed] 8. Wanger J, Clausen JL, Coates A, Pedersen OF, Bru- sasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, Maclntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisa- tion of the measurement of lung volumes. Eur Res- pir J. 2005;26:511-522. [Crossref] 9. Cushing H, Davidoff LM. The pathological findings in four autopsied cases of acromegaly with a discus- sion of their significance Monograph 22, Rockefeller Inst. M. Research; 1927. [Link] 10. Brody JS, Fisher AB, Gocmen A, DuBois AB. Acro- megalic pneumonomegaly: lung growth in the adult. J Clin Invest. 1970;49:1051-1060. [Crossref] [Pubmed] [PMC] 11. Evans CC, Hipkin LJ, Murray GM. Pulmonary func- tion in acromegaly. Thorax. 1977;32:322-327. [Crossref] [Pubmed] [PMC] 12. Trotman-Dickenson B, Weetman AP, Hughes JM. Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med. 1991;79:527-538. [Pubmed] 13. Harrison BD, Millhouse KA, Harrington M, Nabarro JD. Lung function in acromegaly. Q J Med. 1978; 47:517-532. [Pubmed] 14. Siafakas NM, Sigalas J, F